Baseline characteristics
| Safety population . | Value (N = 69) . |
|---|---|
| Age, median (range), y | 64 (25-81) |
| Female sex, n (%) | 32 (46) |
| Race, n (%) | |
| American Indian or Alaska Native | 2 (3) |
| Asian | 29 (42) |
| Black or African American | 3 (4) |
| White | 35 (51) |
| Height, median (range), cm | 165 (142-183) |
| Weight, median (range), kg | 67 (44-109) |
| Body surface area, median (range), m2 | 1.76 (1.4-2.3) |
| Current indication, n (%) | |
| AML | 64 (93) |
| Hypomethylating agents relapse/refractory | 19 (30) |
| Intensive chemotherapy relapsed/refractory | 45 (70) |
| MDS | 5 (7) |
| ECOG performance status, n (%) | |
| 0 | 2 (3) |
| 1 | 54 (78) |
| 2 | 13 (19) |
| Prior treatments, median (range) | |
| AML | 4 (1-14) |
| MDS | 1 (1-2) |
| Safety population . | Value (N = 69) . |
|---|---|
| Age, median (range), y | 64 (25-81) |
| Female sex, n (%) | 32 (46) |
| Race, n (%) | |
| American Indian or Alaska Native | 2 (3) |
| Asian | 29 (42) |
| Black or African American | 3 (4) |
| White | 35 (51) |
| Height, median (range), cm | 165 (142-183) |
| Weight, median (range), kg | 67 (44-109) |
| Body surface area, median (range), m2 | 1.76 (1.4-2.3) |
| Current indication, n (%) | |
| AML | 64 (93) |
| Hypomethylating agents relapse/refractory | 19 (30) |
| Intensive chemotherapy relapsed/refractory | 45 (70) |
| MDS | 5 (7) |
| ECOG performance status, n (%) | |
| 0 | 2 (3) |
| 1 | 54 (78) |
| 2 | 13 (19) |
| Prior treatments, median (range) | |
| AML | 4 (1-14) |
| MDS | 1 (1-2) |
ECOG, Eastern Cooperative Oncology Group.